Gary, that is a good question. The FDA guidance regarding the RTOR clearly says that the new BLA process for a new oncology / cancer treatment can get started just with the top line data from the Phase II or III trial. Please see the excerpt from the FDA’s guidance below:
Market Data 
Markets 
AI
